Structure and Affinity of Cu(I) Bound to Human Serum Albumin

Madison Sendzik1, M Jake Pushie2, Ewelina Stefaniak1,3

  • 1Department of Chemistry and Physics, Saint Mary's College , Notre Dame, Indiana 46556, United States.

Inorganic Chemistry
|November 23, 2017
PubMed

Insights

Human serum albumin (HSA) binds copper(I) (Cu(I)) with high affinity, challenging the assumption that only copper(II) interacts with HSA. This unappreciated Cu(I) interaction may be significant in human extracellular fluids.

Area of Science:

  • Biochemistry
  • Metalloprotein Chemistry
  • Neuroscience

Background:

  • Human serum albumin (HSA) is the primary copper (Cu) carrier in blood and cerebrospinal fluid.
  • Previous research focused on Cu(II)-HSA interactions, assuming Cu(I) binding was negligible.
  • HSA's role in Cu(I) binding and its coordination chemistry remained largely uninvestigated.

Purpose of the Study:

  • To characterize the affinity of HSA for Cu(I).
  • To determine the coordination structure of Cu(I) bound to HSA.
  • To assess the significance of Cu(I)-HSA interactions in biological systems.

Main Methods:

  • Solution competition experiments to determine apparent affinity.
  • X-ray absorption spectroscopy (XAS) to elucidate coordination structure.
  • In silico modeling to complement experimental findings.

Main Results:

  • HSA exhibits a high apparent conditional affinity for Cu(I) (KCu(I):HSA = 1014.0) at pH 7.4.
  • Cu(I) binds to HSA in a digonal coordination, similar to histidine coordination in amyloid beta and prion proteins.
  • This binding occurs despite the common assumption of Cu(II) as the primary species interacting with HSA.

Conclusions:

  • HSA binds Cu(I) with a surprisingly high affinity, suggesting a significant, overlooked role in copper transport.
  • The characterized Cu(I) coordination structure provides insights into metalloprotein interactions.
  • Cu(I)-HSA interactions warrant further investigation for their implications in human physiology and disease.

Related Concept Videos

Drug Distribution: Plasma Protein Binding01:29

Drug Distribution: Plasma Protein Binding

Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
9.5K
Drug Binding to Blood Components01:30

Drug Binding to Blood Components

When drugs enter systemic circulation, they interact with various components of the blood, including proteins such as human serum albumin (HSA), α1-acid glycoprotein (AAG), lipoproteins, globulins, and red blood cells (RBCs).
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
558
Formation of Complex Ions03:45

Formation of Complex Ions

A type of Lewis acid-base chemistry involves the formation of a complex ion (or a coordination complex) comprising a central atom, typically a transition metal cation, surrounded by ions or molecules called ligands. These ligands can be neutral molecules like H2O or NH3, or ions such as CN− or OH−. Often, the ligands act as Lewis bases, donating a pair of electrons to the central atom. These types of Lewis acid-base reactions are examples of a broad subdiscipline called coordination...
26.3K
Factors Affecting Protein-Drug Binding: Drug-Related Factors01:18

Factors Affecting Protein-Drug Binding: Drug-Related Factors

Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
510
Extraction: Advanced Methods00:56

Extraction: Advanced Methods

Metal ions can be separated from one another by complexation with organic ligands–the chelating agent– to form uncharged chelates. Here, the chelating agent must contain hydrophobic groups and behave as a weak acid, losing a proton to bind with the metal. Since most organic ligands used in this process are insoluble or undergo oxidation in the aqueous phase, the chelating agent is initially added to the organic phase and extracted into the aqueous phase. The metal-ligand complex is...
1.2K
Factors Affecting Protein-Drug Binding: Protein-Related Factors01:20

Factors Affecting Protein-Drug Binding: Protein-Related Factors

Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
600